click below
click below
Normal Size Small Size show me how
Oncology BDK
Colon Cancer
| Pharmacologic Category | Generic Name | MOA | Common Indications | Key Side Effects | Clinical Pearls | DDI Contraindications |
|---|---|---|---|---|---|---|
| Pharmacologic Category | Generic Name | MOA | Common Indications | Key Side Effects | Clinical Pearls | DDI Contraindications |
| Antimetabolite (cell cycle S-phase specific) | Fluorouracil (5-FU) (Adrucil) | Inhibits thymidylate synthase | CRC | Diarrhea, mucositis, HFS, myelosuppression (BBW) | early onset of severe toxicities if patient has DPD deficiency | |
| Antimetabolite (cell cycle S-phase specific) | Capecitabine | Inhibits thymidylate synthase | CRC | HFS | ||
| DNA alkylating/crosslinking agents (cell cycle phase non-specific) | Oxaliplatin | intrastrand DNA crosslinking | CRC | peripheral neuropathy, temporary cold-induced neuropathy, cumulative/permanent sensory neuropathy | ||
| Topoisomerase poison (Cell cycle S-phase specific) | Irinotecan | Topo-I inhibitor | mCRC | dose-limiting late onset diarrhea, neutropenia | treat with low dose loperamide until 12 hrs diarrhea free | |
| Checkpoint inhibitor (immunotherapy) | Nivolumab | PD-1 inhibitor | dMMR/MSI-H CRC w/unresectable mets | |||
| Checkpoint inhibitor (immunotherapy) | Ipilimumab | CTLA-4 inhibitor | dMMR/MSI-H CRC w/unresectable mets | |||
| Checkpoint inhibitor (immunotherapy) | Pembrolizumab | PD-1 inhibitor | dMMR/MSI-H CRC w/unresectable mets | immune-mediated infections: pneumonitis, colitis, hepatitis, endocrinopathies, nephritism skin disorders | ||
| Checkpoint inhibitor (immunotherapy) | Dostarlimab | PD-1 inhibitor | dMMR/MSI-H CRC w/unresectable mets | Autoimmune disease | ||
| Tyrosine kinase inhibitor | Cetuximab | Anti-EGFR mAb | RAS WT left-sided mCRC | acneiform rash associated with drug response | ||
| Tyrosine kinase inhibitor | Panitumumab | Anti-EGFR mAb | RAS WT left-sided mCRC | acneiform rash associated with drug response | ||
| Angiogenesis inhibitor | Bevacizumab | Anti-VEGF mAb | mCRC | HTN, bleeding, VTE, proteinuria, wound dehiscence | ||
| Tyrosine kinase inhibitor | Trastuzumab | Anti-HER2 mAb | HER2+ mCRC | LVEF decrease | ||
| Tyrosine kinase inhibitor | Pertuzumab | Anti-HER2 mAb | HER2+ mCRC | acne-like rash, LVEF decrease | ||
| Tyrosine kinase inhibitor | Lapatinib | HER2/EGFR | HER2+ mCRC | HFS, acne-like rash | ||
| Tyrosine kinase inhibitor | Tucatinib | HER2 | HER2+ mCRC | HFS, acne-like rash | ||
| Growth factor receptor antagonist | Fam-trastuzumab deruxtecan | HER2 ADC | HER2+ mCRC | ILD, LVEF decrease, alopecia |